SHANGHAI, Oct. 19, 2025 /PRNewswire/ -- Clover Biopharmaceuticals, Ltd.
2025-10-20 07:00
1102
-- Results indicate potential best-in-class RSV+hMPV±PIV3 combination vaccines, with the potential ...
-- Potential First-in-Class Respiratory Combination Vaccine Candidates SCB-1022 (RSV + hMPV) and SC...
-- U.S. IND clearance and revaccination trial initiation supports the differentiated global opportu...
-- Head-to-head clinical results indicate a potential best-in-class combined efficacy & safety prof...
-- Bivalent SCB-1019 significantly boosted RSV-A and RSV-B neutralizing antibody titers in older ad...
-- Bivalent SCB-1019 significantly boosted RSV-A and RSV-B neutralization titers to approximately 6...
--All CIT patients maintained platelet counts >75 x 109/L at 1-week following chemotherapy plus a s...
--First Chinese RSV PreF Vaccine Candidate to Enter Clinical Trial Stage-- SHANGHAI, Dec. 13, 2023 ...
-- Clover's seasonal influenza vaccine BLA submission has been completed in Brazil, boosting Clover...